webinar register page

Webinar banner
State of the Science 2022 February 24 (8-9amPST//4-5pm GMT)
State of the Science is a town hall scientific discussion on select topics in Type 1 diabetes research. State of the Science is a new way of talking about research in the field of T1D. This series will be a celebration of the power of debate and discussion that women scientists in T1D research bring to the table. The 4th discussion in the series focuses on: Clinical Trials in T1D - integrating technology into T1D trials- making sense of a sea of data

Feb 24, 2022 08:00 AM in Pacific Time (US and Canada)

Webinar logo
* Required information


Linda DiMeglio MD
Center Director Trial Net @Indiana University @Indiana University
Dr. Linda A. DiMeglio works in clinical research with a focus on Type 1 diabetes prevention, beta cell preservation, and new technologies and therapeutics. She is a center director and chairs the publications committee for the TrialNet network and is the PI of the Immune Tolerance Network T1DES study. She has been the medical director of the American Diabetes Association Camp John Warvel since 1998. DiMeglio is director of career development and co-chair of the Pediatric Protocol Development Team at the Indiana University Clinical and Translational Science Institute. She also is an active clinician; she sees patients with diabetes and endocrine disorders in clinic and teaches medical students, residents, house staff and fellows. She serves on the editorial board for Diabetes Care and is a current ISPAD Advisory Council member and a member of the ISPAD Guidelines Editorial Board.
Bridget Wagner PhD
Director of Pancreatic Cell & Metabolic Disease @MIT (Broad) @MIT/The Broad Institute
Bridget Wagner is the director of pancreatic cell biology and metabolic disease in the Chemical Biology and Therapeutic Sciences Program at the Broad Institute of MIT and Harvard, where she is also an institute scientist. Her group's research focuses on the chemical biology of diabetes, with the aim of identifying small molecules capable of increasing pancreatic beta cell number and function and the ultimate goal of discovering new therapeutic approaches for diabetes. Beta cell death, and the consequent deficiency in insulin secretion, is a key feature of type 1 diabetes. For decades, the standard of care for this disease has been insulin therapy by intramuscular injection. In type 2 diabetes, beta-cell function is impaired, which is thought to be due to beta-cell death and dedifferentiation. While cell-based treatments show promise, a chemical intervention capable of restoring glycemic control in diabetes would have enormous impact clinically.
Marissa Hilliard PhD
Assistant Professor @Baylor College of Medicine
The lab’s work includes observational and survey research to understand how different risk and protective factors relate to or predict resilient diabetes outcomes, qualitative interview studies to learn about everyday life experiences with diabetes, studies to develop and evaluate new assessment measures related to these topics, and strengths-based intervention research to help young people and families living with diabetes maximize their strengths and achieve optimal outcomes
Marina Basina MD
Clinical Endocrinologist/Researcher @Stanford University
Dr Basina is a clinical endocrinologist and clinical researcher with a focus on diabetes management, thyroid, and adrenal conditions. Her primary interests are in Type 1 Diabetes, Diabetes technology, and Diabetes in pregnancy. Dr Basina is Board certified in Endocrinology and Internal Medicine. She received numerous teaching awards and Stanford Hospital award for excellence in patient care. She is an active member of medical advisory boards for several community diabetes organizations. Dr Basina is a medical director of inpatient diabetes program at Stanford and a chair of diabetes task force.